MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-06826647
Drug: Oral Contraceptive (OC)
First Posted Date
2019-10-22
Last Posted Date
2020-02-05
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT04134715
Locations
🇺🇸

Quotient Sciences-Miami, Miami, Florida, United States

🇺🇸

Quotient Sciences Screening Office, Coral Gables, Florida, United States

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Phase 1
Completed
Conditions
Dermatitis Atopic
Interventions
Drug: PF-07038124 or vehicle
Drug: PF-07038124 and Vehicle
First Posted Date
2019-10-22
Last Posted Date
2020-05-14
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT04135560
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

Phase 2
Terminated
Conditions
Gram-negative Bacterial Infection
First Posted Date
2019-10-14
Last Posted Date
2024-03-26
Lead Sponsor
Pfizer
Target Recruit Count
48
Registration Number
NCT04126031
Locations
🇬🇷

"ATTIKON" University General Hospital, Chaidari, Athens, Greece

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Tufts Children's Hospital at Tufts Medical Center, Boston, Massachusetts, United States

and more 15 locations

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Phase 1
Withdrawn
Conditions
Pharmacokinetics
Interventions
Drug: bevacizumab - EU
Drug: PF-06439535 (CN)
First Posted Date
2019-10-14
Last Posted Date
2021-04-27
Lead Sponsor
Pfizer
Registration Number
NCT04126044
Locations
🇨🇳

Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Relative Bioavailability
Drug: PF-06842874
Drug: Placebo
First Posted Date
2019-10-11
Last Posted Date
2021-12-06
Lead Sponsor
Pfizer
Target Recruit Count
44
Registration Number
NCT04124653
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Completed
Conditions
Metastatic Renal Cell Carcinoma ( mRCC)
Interventions
First Posted Date
2019-10-03
Last Posted Date
2022-05-10
Lead Sponsor
Pfizer
Target Recruit Count
57
Registration Number
NCT04115189
Locations
🇧🇷

Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil

🇦🇷

Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina

🇦🇷

Sanatorio del Salvador - Cordoba, Cordoba, Argentina

and more 4 locations

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-10-01
Last Posted Date
2020-01-13
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT04111614
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

Vyndaqel Capsules Special Investigation (ATTR-CM)

Active, not recruiting
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Drug: Treatment for TTR amyloidosis
First Posted Date
2019-09-27
Last Posted Date
2024-10-10
Lead Sponsor
Pfizer
Target Recruit Count
1214
Registration Number
NCT04108091
Locations
🇯🇵

Pfizer, Tokyo, Japan

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

Phase 1
Completed
Conditions
HEALTHY
Interventions
First Posted Date
2019-09-23
Last Posted Date
2020-01-02
Lead Sponsor
Pfizer
Target Recruit Count
13
Registration Number
NCT04099563
Locations
🇨🇳

Beijing Hospital Sub-Center of Beijing Hospital Clinical Trial & Research Center, Beijing, China

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Phase 2
Completed
Conditions
Acne Inversa
Interventions
Drug: PF-06650833
Drug: PF-06700841
Drug: PF-06826647
Drug: Placebo
First Posted Date
2019-09-17
Last Posted Date
2023-06-15
Lead Sponsor
Pfizer
Target Recruit Count
194
Registration Number
NCT04092452
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

Dermatology Associates of Seattle, Seattle, Washington, United States

🇺🇸

Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 72 locations
© Copyright 2025. All Rights Reserved by MedPath